Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated by Analysts at assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRVGet Rating) in a research note issued on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Nabriva Therapeutics Trading Down 5.0 %

NBRV stock opened at $0.17 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.05 and a current ratio of 4.01. Nabriva Therapeutics has a one year low of $0.16 and a one year high of $1.40. The company has a market capitalization of $107.76 million, a PE ratio of -0.18 and a beta of 1.49. The company’s 50 day moving average price is $0.19 and its two-hundred day moving average price is $0.33.

Nabriva Therapeutics (NASDAQ:NBRVGet Rating) last announced its earnings results on Thursday, May 5th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Nabriva Therapeutics had a negative net margin of 137.52% and a negative return on equity of 82.07%. The business had revenue of $8.02 million for the quarter, compared to the consensus estimate of $9.58 million. During the same quarter last year, the firm posted ($0.53) EPS. As a group, analysts predict that Nabriva Therapeutics will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Nabriva Therapeutics stock. Frazier Life Sciences Management L.P. acquired a new position in shares of Nabriva Therapeutics plc (NASDAQ:NBRVGet Rating) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 425,650 shares of the biotechnology company’s stock, valued at approximately $179,000. Frazier Life Sciences Management L.P. owned 0.07% of Nabriva Therapeutics at the end of the most recent reporting period. Institutional investors own 1.55% of the company’s stock.

Nabriva Therapeutics Company Profile

(Get Rating)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.

Recommended Stories

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with's FREE daily email newsletter.